Nature nanotechnologyOct 30, 2025

A flexible mRNA system to trigger immune-targeted cancer cell death

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

TITUR is a customizable mRNA nanomedicine platform that may focus immunogenic cell death induction within tumours.

Evidence

This preclinical platform study tested tumour-customizable ionizable lipids and untranslated regions for 4HB mRNA delivery in murine melanoma and triple-negative breast cancer models, including combinations with immune checkpoint inhibitors.

Caveat

The evidence is limited to mouse tumour models and platform comparisons, so human efficacy, personalization feasibility, and long-term safety remain unproven.

Simplified

Messenger RNA (mRNA) therapeutics hold great promise for oncology but their efficacy is limited by systemic off-target effects and immunosuppressive tumour microenvironments. Here we present TITUR, a tumour-customizable mRNA nanomedicine platform that integrates tumour-customizable ionizable lipids (TIs) and tumour-specific untranslated regions (TURs) to enhance tumour-selective mRNA delivery and expression. This dual-engineered approach enables the precise intratumoural expression of 4HB, an immunogenic cell death-inducing protein, while mitigating systemic toxicities. Using murine models of immunologically cold tumours, including melanoma and triple-negative breast cancer, TITUR-mediated 4HB delivery induced tumour-specific immunogenic cell death, remodelled the tumour microenvironment and enhanced immune cell infiltration. When combined with immune checkpoint inhibitors, 4HB TITUR suppressed primary and metastatic tumour growth, while also exhibiting vaccine-like properties by reducing tumour recurrence and eliciting systemic antitumour immunity. Furthermore, it demonstrated a superior safety profile compared with conventional mRNA delivery methods. Our data indicate that TITUR may serve as a versatile approach to address the limitations of current immunotherapies and support the development of personalized mRNA nanomedicines.